Page 251 - 2021_03-Haematologica-web

Letters to the Editor
Prithviraj Bose,3 Alessandra Ferrajoli,3 Ghayas C. Issa,3 Elias J. Jabbour,3 Lucia Masarova,3 Philip A. Thompson,3 Sa Wang,4 Sergej Konoplev,4 Sherry A. Pierce,3 Jing Ning,5 Wei Qiao,5 John S. Welch,6 Hagop M. Kantarjian,3 Courtney D. DiNardo3 and Marina Y. Konopleva3
1Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; 2Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX; 3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; 4Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston,TX; 5Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX and 6Divisions of Hematology and Oncology, Washington University School of Medicine in St. Louis, MO, USA
Correspondence:
COURTNEY D. DINARDO - CDiNardo@mdanderson.org MARINA Y. KONOPLEVA - mkonople@mdanderson.org doi:10.3324/haematol.2020.252569
Disclosures: AM has received research funding from Celgene Corporation; JEC has received research funding from Ambit BioSciences, ARIAD, Arog, Astellas Pharma, AstraZeneca, Bristol- Myers Squibb, Celator, Celgene, Novartis, Pfizer, Sanofi, Sun Pharma, and Teva; and has had a consultancy role with Ambit BioSciences, ARIAD, Astellas Pharma, BiolineRx, Bristol-Myers Squibb, Novartis, and Pfizer. NP has had a consultancy role or received honoraria from Celgene, Stemline, Incyte, Novartis, MustangBio, Roche Diagnostics, and LFB; research funding/clinical trial support from Stemline, Novartis, Abbvie, Samus, Cellectis, Plexxikon, Daiichi-Sankyo, and Affymetrix; grants or funding from Affymetrix, and SagerStrong Foundation. NGD has had a consultan- cy role with and received research funding from Sunesis Pharmaceuticals Inc., Karyopharm, Pfizer Inc., and Bristol-Myers Squibb Company; consultancy fees from Novartis Pharmaceuticals Corporation, Otsuka America Pharmaceutical Inc., and Jazz; research funding from Immunogen, Daiichi-Sankyo, and Kiromic; honoraria and research funding from Incyte Corporation. FR has received research funding from Amgen, Bristol-Myers Squibb, Merck, Seattle Genetics, and Sunesis Pharmaceuticals; honoraria from Amgen, Pfizer, Seattle Genetics, and Sunesis Pharmaceuticals; has had a consulting or advi- sory role for Amgen, Seattle Genetics, and Sunesis Pharmaceuticals. GB has received research funding from AbbVie, Incyte, Janssen, GSK, Cyclacel and Oncoceutics Inc.; and has had a consultancy role with NKarta and PTC Therapeutics; has had a consultancy role with and research funding from BioLine Rx. NJS has had a consultancy role with and research funding from Takeda Oncology; has had a consul- tancy role with AstraZeneca; has received honoraria from Amgen. YA has received research funding from Jazz Pharmaceuticals; honoraria from Abbott. KT has had a consultancy role with Symbio Pharmaceuticals. NJ has had a consultancy role, has received honorar- ia, and is a member of an entity's Board of Directors or sits on advisory committees, and has received research funding from AbbVie, Pharmacyclics, Genentech, Pfizer, ADC Therapeutics, AstraZeneca, Servier, Verastem, Precision Biosciences, and Adaptive Biotechnologies; has had a consultancy role, has received honoraria, and is a member of an entity's Board of Directors or sits on advisory committees, Janssen Pharmaceuticals Inc.; has received research funding from BMS, Incyte, and Cellectis. KS has received honoraria from Otsuka; has had a con- sultancy role with Pfizer. MA has had a consultancy role, and declares patents and royalties, and to have received research funding from Daiichi Sankyo, Inc.; has had a consultancy role with Jazz Pharmaceuticals, Celgene, Amgen. AstraZeneca, and 6 Dimensions Capital; he has equity ownership in Reata, Aptose, Eutropics, Oncoceutics, and Oncolyze and ia a member of an entity's Board of Directors or sits on advisory committees for Senti Bio; has received research funding from Breast Cancer Research Foundation, CPRIT, and NIH/NCI; is a member of an entity's Board of Directors or sits on
advisory committees for the Center for Drug Research & Development, Cancer UK, NCI-CTEP, German Research Council, Leukemia Lymphoma Society, NCI-RDCRN (Rare Disease Clin Network), CLL Foundation, and BiolineRx; PB has had a consultancy role, has received research funding and sits on the speakers’ bureau for Incyte Corporation; has had a consultancy role and has received research funding from Celgene Corporation and Blueprint Medicines Corporation; has received research funding from Kartos Therapeutics, Constellation Pharmaceuticals, Pfizer, Astellas Pharmaceuticals, NS Pharma Research, Promedior, and CTI BioPharma; EJJ has had a consultancy role with and has received research funding from Takeda, BMS, Adaptive, Amgen, AbbVie, Pfizer, and Cyclacel Ltd. JSW has received honoraria from ArcherDx and Rigel Pharmaceuticals, and research funding from Jansen Pharmaceuticals and Notable Laboratories. CDD has received honoraria and research funding from AbbVie, Agios, Novartis, Celgene, and Daiichi-Sankyo, and research funding from Calithera Biosciences, honoraria from Jazz Pharmaceuticals, honoraria from and is a member of a scientific adviso- ry board for Notable Laboratories. HMK has received research funding from ARIAD, Astex, BMS, Cyclacel, Daiichi-Sankyo, Jazz, and Novartis, honoraria and research funding from Pfizer and Immunogen, and honoraria from Actinium and Takeda. MYK has received research funding from Calithera, Eli Lilly, Cellectis, Ascentage, AstraZeneca and Agios, has had a consultancy role with and received honoraria from Forty-Seven, Amgen, and Kisoji; has had a consultancy role with and has received honoraria and research funding from Stemline Therapeutics, Abbvie, and F. Hoffman La-Roche, honoraria and research funding from Genentech, research funding from Ablynx; has equity ownership and patents and royalties from Reata Pharmaceuticals. CRR, GGM, KN, MO, TMK, MY, SK, GMB, AF, GCI, LM, PAT, SAW, SK, SAP, JN and WQ have no conflicts of interest to disclose.
Contributions: AM, CDD, MYK, CDD, MYK, GGM, HMK, JEC, GGM administrative support; CRR, JEC, NP, NGD, FR, GGM, GB, KN, MO, NJS, YA, CBB, TMK, KT, MY, NJ, SK, GMB, KS, A, PB, AF, GCI, EJJ, LM, PAT, SW, SJ, MG, REM, JAG, CAB, AW, SLA, ST, RT, KV, SAP, JN, WQ, JSW, HMK, MYK, CDD provision of study materials or patients; CRR, JEC, NP, NGD, FR, GGM, GB, KN, MO, NJS, YA, CBB, TMK, KT, MY, NJ, SK, GMB, KS, A, PB, AF, GCI, EJJ, LM, PAT, SW, SJ, MG, REM, JAG, CAB, AW, SLA, ST, RT, KV, SAP, JN, WQ, JSW, HMK, MYK, CDD collection and assembly of data; AM, CDD, MYK, CRR, JN, WQ, QZ, AC, HM, SAW, SNK, ZC, MG data analysis and interpretation; AM, CDD, MYK manuscript writing; all authors critical revision for important intellectual content and reviewed and approved the final version of the manuscript.
Acknowledgments: we thank the patients, their families, and their caregivers, co-investigators, collaborators, and members of the study team involved in the trial.
Funding: this study was supported in part by the MD Anderson Cancer Center Support Grant CA016672 from the National Cancer Institute, and Research Project Grant Program (R01CA235622) from the National Institutes of Health.
References
1.Martin MG, Abboud CN. Induction therapy for elderly patients with acute myeloid leukemia. Blood Rev. 2008;22(6):311-320.
2. Silva P, Neumann M, Schroeder MP, et al. Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape. Leukemia. 2017;31(7):1640-1644.
3. Kantarjian H, Ravandi F, O’Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116(22):4422-4429.
4. DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7-17.
5. Maiti A, DiNardo CD, Rausch CR, et al. Ten-day decitabine with venetoclax (DEC10-VEN) in acute myeloid leukemia: updated results of a phase II Trial. Blood. 2019;134(Suppl 1):2637.
6. AbbVie Announces Positive Topline Results from Phase 3 Trial of
haematologica | 2021; 106(3)
897